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Clinical Trial
Darapladib Significantly Lowers Lp-PLA2 Activity
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a biomarker of cardiovascu-lar risk that contributes to the proatherosclerotic tendencies of oxidized low-
density lipoprotein. This placebo-controlled, dose-ranging study examined the effects
of darapladib, a selective Lp-PLA2 inhibitor, on biomarkers of cardiovascular risk, but
was too short to identify any clinical benefit.Darapladib inhibited Lp-PLA2 activity by
up to 66% for the highest dose. Interleukin-6 and high-sensitivity C-reactive protein
were also substantially lowered. No major safety concerns were noted. Darapladib
appears to produce a sustained inhibition of plasma Lp-PLA2 activity in patients
receiving atorvastatin; further studies will determine if this results in better outcomes.
See pages 1632 and 1642. See figure.
Heart Failure
Weak Diaphragms May Contribute
to Fatigue and Vasoconstriction in CHF Patients
Previous research has demonstrated that the inspiratory muscles of the diaphragmmay shift to anaerobic metabolism when they become fatigued. Through the
inspiratory muscle metaboreflex, this may lead to shunting of blood from other
vascular beds to the diaphragm. Chiappa and colleagues hypothesized that this reflex
may be accentuated in patients with chronic heart failure (CHF) and could be
overcome through training of thesemuscles. Inspiratorymuscle fatiguewas induced by
having subjects breathe through a small tube during hand exercise while measuring
blood flow to the calf and forearm. Experiments were repeated after 4 weeks of
inspiratory muscle training. Subjects with CHF showed marked vasoconstriction
during exercise,whichwas attenuated after the respiratory training.This studyprovides
evidence of abnormal activity of the inspiratory muscle metaboreflex in patients with
CHF and suggests that it can be attenuated by training of the inspiratory muscles.
See pages 1663 and 1672.
Heart Rhythm Disorders
Registry of ICD Implants in Pediatric and Congenital Heart Patients
Berul and colleagues retrospectively obtained data from 4 pediatric centers, aimingto identify implant characteristics, shock frequency, and complication rates for
pediatric or adult patients with congenital heart disease (CHD)who received implant-
able cardioverter-defibrillators (ICDs).They identified443patients,with amedian age
of 16 years; 69% had structural heart disease and the others had electrical anomalies.
One-half of patients received the device for primary prevention. Twenty-six percent
received appropriate shocks, and 21% received inappropriate shocks, mainly due to
lead failure (14%). The authors conclude that children andCHD ICD recipients have
significant appropriate and inappropriate shocks; the number of inappropriate shocks
may be reduced by better device programming, medical management, patient compli-
ance, and reducing the lead failure rate. See page 1685.
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Heart Rhythm Disorders
Mitral Annuloplasty May Frequently Result in Functional Mitral Stenosis
Whenpatients referred for coronary artery bypass graft surgery are found to havemitral regurgitation, many have advocated simultaneous placement of amitral
valve annuloplasty (MVA) ring. By convention, the size of the ring is usually 2 to 4mm
smaller than the pre-surgical intertrigonal width. Magne and colleagues performed
resting and dobutamine stress echocardiography and 6-min walk test (6MWT) in 24
patients without recurrent mitral regurgitation after restrictive MVA. Compared to a
matched control group, MVA patients had higher transmitral pressure gradients,
higher pulmonary artery pressures, and reduced6MWTdistance.These results suggest
that performing a restrictive MVA in patients with ischemic mitral regurgitation may
create a functional mitral stenosis that may impair functional capacity. See pages
1692 and 1702. See figure.
